Cryptococcosis Therapeutics Global Market Report 2025
상품코드:1810863
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
크립토콕쿠스증 치료제 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 CAGR 5.3%로 50억 7,000만 달러로 성장할 것입니다. 예측 기간 동안의 성장은 항진균제 연구 및 신약 개발에 대한 투자 증가, 면역억제 상태 및 치료 보급률 증가, 전 세계 진균성 질환의 부담 증가, 신속한 진단 도구 및 병용요법에 대한 수요 증가 등에 기인하는 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 항진균제 병용 치료로의 전환, 혁신적인 기전의 차세대 항진균제 개발, 진균증 관리의 통합 강화, 첨단 약물전달 기술 도입, 인공지능 및 머신러닝 도입 등을 들 수 있습니다.
인간면역결핍바이러스(HIV) 또는 후천성면역결핍증후군(AIDS)의 유병률 증가는 향후 몇 년 동안 크립토콕쿠스증 치료제 시장의 성장을 촉진할 것으로 예상됩니다. HIV/AIDS는 면역체계를 공격하는 바이러스에 의해 발생하는 만성적이고 생명을 위협하는 질병으로, 감염과 질병에 걸리기 쉽습니다. 특정 지역에서의 유병률 증가는 의료 서비스에 대한 접근성이 제한되어 조기 진단, 지속적인 치료 및 효과적인 예방에 영향을 미치고 있기 때문입니다. 크립토콕쿠스증 치료제는 면역결핍 환자에서 흔히 발생하는 기회성 진균 감염을 대상으로 하기 때문에 HIV/AIDS 관리에 매우 중요합니다. 이러한 치료제는 크립토코커스 수막염과 같은 심각한 합병증 위험을 줄여 환자의 예후를 개선하고 삶의 질을 향상시키며 장기적인 질병 관리를 돕습니다. 예를 들어, 2024년 10월 영국 보건안전국은 2023년 영국 내 HIV 감염자 수(해외에서 진단된 사례 포함)를 6,008명으로 보고했으며, 이는 2022년 3,975명에서 51% 증가한 수치입니다. 그 결과, HIV/AIDS의 유병률 증가는 크립토콕쿠스증 치료제 시장을 촉진하고 있습니다.
또한, 헬스케어 지출 증가도 크립토콕쿠스증 치료제 시장 성장에 크게 기여할 것으로 예상됩니다. 헬스케어 지출에는 의료 서비스, 치료, 연구, 시설, 건강 결과를 개선하기 위한 공중 보건 프로그램에 지출되는 모든 재원이 포함됩니다. 이러한 증가는 더 많은 의료 및 장기적인 건강관리 서비스를 필요로 하는 고령화에 의해 크게 좌우됩니다. 의료비 지출 증가는 고급 치료에 대한 접근성을 개선하고, 조기 진단을 용이하게 하며, 보다 효과적인 항진균제 연구에 자금을 지원함으로써 크립토콕쿠스증 치료제를 뒷받침하고 있습니다. 예를 들어, 2024년 12월 미국 메디케어-메디케이드 서비스 센터(CMS)는 2023년 미국 국민 의료비가 7.5% 증가한 4조 9,000억 달러로 국내총생산(GDP)의 17.6%를 차지할 것이라고 보고했습니다. 또한, 2023년부터 2032년까지 국민의료비는 연평균 5.6% 성장하고, GDP에서 보건의료가 차지하는 비중은 2022년 17.3%에서 2032년 19.7%로 증가할 것으로 예측됩니다. 따라서 의료비 지출 증가가 크립토콕쿠스증 치료제 시장 성장을 주도하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 크립토콕쿠스증 치료제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 크립토콕쿠스증 치료제 시장 : 성장률 분석
세계의 크립토콕쿠스증 치료제 시장 실적 : 규모와 성장, 2019-2024
세계의 크립토콕쿠스증 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 크립토콕쿠스증 치료제 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 크립토콕쿠스증 치료제 시장 : 약제 종류별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
브랜드
제네릭
세계의 크립토콕쿠스증 치료제 시장 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
Amphotericin B
Flucytosine
Fluconazole
기타 치료법
세계의 크립토콕쿠스증 치료제 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구
정맥내
흡입
세계의 크립토콕쿠스증 치료제 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
세계의 크립토콕쿠스증 치료제 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
외래 수술 센터
기타 최종사용자
세계의 크립토콕쿠스증 치료제 시장 : 하위 세분화 브랜드 의약품(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
Ambisome
Diflucan
Vfend
Noxafil
Cresemba
세계의 크립토콕쿠스증 치료제 시장 : 하위 세분화 제네릭 의약품(종류별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
Amphotericin B Deoxycholate
Fluconazole
Voriconazole
Itraconazole
Flucytosine
제7장 지역별·국가별 분석
세계의 크립토콕쿠스증 치료제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 크립토콕쿠스증 치료제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
크립토콕쿠스증 치료제 시장 : 경쟁 구도
크립토콕쿠스증 치료제 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
Bayer AG Overview, Products and Services, Strategy and Financial Analysis
Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Asahi Kasei Pharma Corporation
Astellas Pharma Inc.
Bausch Health Companies Inc.
Sun Pharmaceutical Industries Limited
Eisai Co. Ltd.
Dr. Reddy's Laboratories Ltd.
Cipla Limited
Takeda Pharmaceutical Company Limited
Luminex Corporation
Evotec SE
Kaken Pharmaceutical Co. Ltd.
Basilea Pharmaceutica AG
Vical Incorporated
F2G Limited
Century Pharmaceuticals Ltd.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
크립토콕쿠스증 치료제 시장 2029 : 새로운 기회를 제공하는 국가
크립토콕쿠스증 치료제 시장 2029 : 새로운 기회를 제공하는 부문
크립토콕쿠스증 치료제 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
KSM
영문 목차
영문목차
Cryptococcosis therapeutics encompass the range of medical treatments aimed at managing cryptococcosis, a serious fungal infection primarily caused by Cryptococcus neoformans or Cryptococcus gattii. This infection mainly affects individuals with compromised immune systems. The primary goal of these treatments is to control the spread of the fungus, alleviate symptoms, and prevent severe complications such as meningitis.
The main categories of cryptococcosis therapeutics include branded and generic drugs. Branded medications are prescription drugs marketed under trademarked names by pharmaceutical companies. These treatments involve drugs like amphotericin B, flucytosine, fluconazole, among others, and can be administered orally, intravenously, or via inhalation. Distribution channels for these therapeutics include hospital pharmacies, retail pharmacies, and online pharmacies, catering to end users such as hospitals, ambulatory surgical centers, and related healthcare facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The cryptococcosis therapeutics market research report is one of a series of new reports from The Business Research Company that provides cryptococcosis therapeutics market statistics, including cryptococcosis therapeutics industry global market size, regional shares, competitors with a cryptococcosis therapeutics market share, detailed cryptococcosis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the cryptococcosis therapeutics industry. This cryptococcosis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cryptococcosis therapeutics market size has grown strongly in recent years. It will grow from $3.91 billion in 2024 to $4.13 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth during the historic period can be attributed to the increasing prevalence of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS), heightened awareness of fungal infections, improved availability of antifungal medications, expansion of global surveillance and fungal disease awareness programs, and the rise of non-governmental health initiatives.
The cryptococcosis therapeutics market size is expected to see strong growth in the next few years. It will grow to $5.07 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The projected growth in the forecast period can be attributed to increasing investments in antifungal research and novel drug development, the rising prevalence of immunosuppressive conditions and treatments, the growing global burden of fungal diseases, and the heightened demand for rapid diagnostic tools and combination therapies. Key trends expected during this period include a move toward combination antifungal treatments, the development of next-generation antifungals with innovative mechanisms, enhanced integration of fungal disease management, adoption of advanced drug delivery technologies, and the incorporation of artificial intelligence and machine learning.
The increasing prevalence of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) is anticipated to drive the growth of the cryptococcosis therapeutics market in the coming years. HIV/AIDS is a chronic and life-threatening condition caused by a virus that attacks the immune system, making individuals more susceptible to infections and diseases. The rising prevalence in certain areas is attributed to limited access to healthcare services, which affects early diagnosis, continuous treatment, and effective prevention. Cryptococcosis therapeutics are crucial for managing HIV/AIDS as they target opportunistic fungal infections that commonly affect immunocompromised patients. These therapeutics improve patient outcomes by reducing the risk of severe complications like cryptococcal meningitis, thereby enhancing quality of life and supporting long-term disease management. For example, in October 2024, the UK Health Security Agency reported 6,008 HIV diagnoses in England for 2023 (including cases diagnosed abroad), reflecting a 51% increase from 3,975 cases in 2022. Consequently, the growing prevalence of HIV/AIDS is propelling the cryptococcosis therapeutics market.
Rising healthcare expenditure is also expected to contribute significantly to the growth of the cryptococcosis therapeutics market. Healthcare expenditure includes all financial resources spent on medical services, treatments, research, facilities, and public health programs aimed at improving health outcomes. This increase is largely driven by an aging population that requires more medical care and long-term healthcare services. Higher healthcare spending supports cryptococcosis therapeutics by improving access to advanced treatments, facilitating early diagnosis, and funding research into more effective antifungal drugs. For instance, in December 2024, the Centers for Medicare & Medicaid Services (CMS) reported that national health expenditures in the U.S. rose by 7.5% to $4.9 trillion in 2023, representing 17.6% of the gross domestic product (GDP). Moreover, between 2023 and 2032, national health expenditures are projected to grow at an average annual rate of 5.6%, increasing healthcare's share of GDP from 17.3% in 2022 to 19.7% in 2032. Therefore, rising healthcare expenditure is driving market growth for cryptococcosis therapeutics.
Key companies in the cryptococcosis therapeutics market are focused on developing innovative treatments and securing regulatory approvals for drugs like azole antifungals to improve efficacy, address drug resistance, and expand their market share. Azole antifungal drugs inhibit fungal growth by blocking the synthesis of ergosterol, a critical component of fungal cell membranes. For example, in December 2022, Asahi Kasei Pharma Corporation, a pharmaceutical company based in Japan, obtained approval from Japan's Ministry of Health, Labour, and Welfare (MHLW) to manufacture and sell Cresemba capsules (100 mg) and intravenous infusion (200 mg) for treating serious fungal infections such as aspergillosis, mucormycosis, and cryptococcosis. Cresemba (isavuconazonium sulfate) works by disrupting ergosterol production, causing fungal cell death. The capsules are approved for patients aged six years and older (weighing at least 16 kg), while the intravenous form is suitable for patients aged one year and above.
Major players in the cryptococcosis therapeutics market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences Inc., Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Limited, Eisai Co. Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Takeda Pharmaceutical Company Limited, Luminex Corporation, Evotec SE, Kaken Pharmaceutical Co. Ltd., Basilea Pharmaceutica AG, Vical Incorporated, F2G Limited, Century Pharmaceuticals Ltd., LGM Pharma LLC, Zeon Health Industries Pvt. Ltd., and Matinas BioPharma Holdings Inc.
North America was the largest region in the cryptococcosis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cryptococcosis therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the cryptococcosis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cryptococcosis therapeutics market consists of revenues earned by entities by providing services such as diagnosis, antifungal drug administration, patient monitoring, treatment planning, disease management, and post-treatment care. The market value includes the value of related goods sold by the service provider or included within the service offering. The cryptococcosis therapeutics market also includes sales of polyene antifungals, azole antifungals, pyrimidine analogues, protein/enzyme inhibitors, and repurposed drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cryptococcosis Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cryptococcosis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cryptococcosis therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cryptococcosis therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Type: Branded; Generic
2) By Treatment: Amphotericin B; Flucytosine; Fluconazole; Other Treatments
3) By Route Of Administration: Oral; Intravenous; Inhalation
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Ambulatory Surgical Centers; Other End Users
Subsegments:
1) By Branded Drugs: Ambisome; Diflucan; Vfend; Noxafil; Cresemba
2) By Generic Drugs: Amphotericin B Deoxycholate; Fluconazole; Voriconazole; Itraconazole; Flucytosine
3. Cryptococcosis Therapeutics Market Trends And Strategies
4. Cryptococcosis Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Cryptococcosis Therapeutics Growth Analysis And Strategic Analysis Framework
5.1. Global Cryptococcosis Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Cryptococcosis Therapeutics Market Growth Rate Analysis
5.4. Global Cryptococcosis Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Cryptococcosis Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Cryptococcosis Therapeutics Total Addressable Market (TAM)
6.1. Global Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Branded
Generic
6.2. Global Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Amphotericin B
Flucytosine
Fluconazole
Other Treatments
6.3. Global Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
Inhalation
6.4. Global Cryptococcosis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Cryptococcosis Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Ambulatory Surgical Centers
Other End Users
6.6. Global Cryptococcosis Therapeutics Market, Sub-Segmentation Of Branded Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ambisome
Diflucan
Vfend
Noxafil
Cresemba
6.7. Global Cryptococcosis Therapeutics Market, Sub-Segmentation Of Generic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Amphotericin B Deoxycholate
Fluconazole
Voriconazole
Itraconazole
Flucytosine
7. Cryptococcosis Therapeutics Market Regional And Country Analysis
7.1. Global Cryptococcosis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Cryptococcosis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Cryptococcosis Therapeutics Market
9.1. China Cryptococcosis Therapeutics Market Overview
9.2. China Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Cryptococcosis Therapeutics Market
10.1. India Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Cryptococcosis Therapeutics Market
11.1. Japan Cryptococcosis Therapeutics Market Overview
11.2. Japan Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Cryptococcosis Therapeutics Market
12.1. Australia Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Cryptococcosis Therapeutics Market
13.1. Indonesia Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Cryptococcosis Therapeutics Market
14.1. South Korea Cryptococcosis Therapeutics Market Overview
14.2. South Korea Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Cryptococcosis Therapeutics Market
15.1. Western Europe Cryptococcosis Therapeutics Market Overview
15.2. Western Europe Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Cryptococcosis Therapeutics Market
16.1. UK Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Cryptococcosis Therapeutics Market
17.1. Germany Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Cryptococcosis Therapeutics Market
18.1. France Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Cryptococcosis Therapeutics Market
19.1. Italy Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Cryptococcosis Therapeutics Market
20.1. Spain Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Cryptococcosis Therapeutics Market
21.1. Eastern Europe Cryptococcosis Therapeutics Market Overview
21.2. Eastern Europe Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Cryptococcosis Therapeutics Market
22.1. Russia Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Cryptococcosis Therapeutics Market
23.1. North America Cryptococcosis Therapeutics Market Overview
23.2. North America Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Cryptococcosis Therapeutics Market
24.1. USA Cryptococcosis Therapeutics Market Overview
24.2. USA Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Cryptococcosis Therapeutics Market
26.1. South America Cryptococcosis Therapeutics Market Overview
26.2. South America Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Cryptococcosis Therapeutics Market
27.1. Brazil Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Cryptococcosis Therapeutics Market
28.1. Middle East Cryptococcosis Therapeutics Market Overview
28.2. Middle East Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Cryptococcosis Therapeutics Market
29.1. Africa Cryptococcosis Therapeutics Market Overview
29.2. Africa Cryptococcosis Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Cryptococcosis Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Cryptococcosis Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Cryptococcosis Therapeutics Market Competitive Landscape And Company Profiles
